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Ovarian cancer occ�pies the place among the 
leading ca�ses of death from gynecological cancer. 
Altho�gh the �-year s�rvival rate for all stages has 
improved recently�� it is still disappointingly low �3�%���� 
largely beca�se that there is no efficient methods for 
diagnosis and therapy [�]. So it is important to search 
for a biomarker identifying high risk patients.
S�rvivin is a member of the inhibitor of apoptosis 
protein �IAP�� family and has been implicated in both 
apoptosis inhibition and cell cycle control [��� 3]. It is 
aberrantly expressed in vario�s kinds of cancer cells 
b�t is �ndetectable in normal differentiated ad�lt tis-
s�es�� except testis�� thym�s�� and placenta [4]. More-
over�� many st�dies have reported that the expression 
rate of s�rvivin in t�mor tiss�es is associated with 
t�mor progression and �nfavorable clinicopathologic 
variables�� s�ch as poor prognosis�� shorter patient 
s�rvival rates and chemoresistance [����]. 
S�rvivin is expressed in h�man carcinomas�� b�t its 
expression levels in tiss�es are different�� that is associ-
ated with the poor o�tcome of patients [�3��4]. Many 
st�dies have demonstrated that rate of expression 
and s�bcell�lar localization of s�rvivin correlated with 
the progression and prognosis of ovarian carcinoma 
[����8]. In this st�dy�� we �sed QRT-PCR to analyze 
s�rvivin expression levels in benign ovarian t�mors�� 
ovarian carcinomas of different stages in order to 
identify these correlations. It was shown that the high 
s�rvivin mRNA expression is implicated in ovarian 
carcinoma progression and may serve as a prognostic 
marker for ovarian carcinoma patients.
Materials and Methods
Patients and tissue handling. Fresh ovarian tis-
s�es were obtained with Instit�tional Review Board 
approved informed consent from patients treated 
by the Department of Gynecologic & Obstetrics at 
Qil� hospital of Shandong University between De-
cember ���� and ��ly ���6�� and incl�de 63 cases 
of ovarian carcinoma�� �� cases of borderline ovarian 
carcinoma�� �� cases of benign ovarian t�mor�� and 
�� samples of normal ovarian tiss�e from patients 
who �nderwent total abdominal hysterectomy with 
salpingo-oopherectomy for non-malignant gyneco-
logic disease. The patients ranged in age from �� to 
��� years ���.3 ± ��.6 years; median age�� �6 years��. 
The staging and grading of t�mors were determined 
in accordance with the International Federation of 
Gynecology and Obstetrics �FIGO�� criteria ���8��� for 
malignant ovarian carcinoma; �8 t�mors were classi-
fied as early stage �I/II�� and 3� — as advanced stage 
�III/IV��; 3� cases were at low grade �G��G����� and 
33 — at high grade�G3��. Histological types incl�ded 
sero�s �n = 4����� m�cino�s �n = ������ and endometrioid 
�n = ���. There were 34 cases with lymph node metas-
tasis and 36 cases with ascites. All tiss�e specimens 
were immediately frozen in liq�id nitrogen and then 
stored in �8� °C �ntil �se.
RNA extraction and reverse transcription. Total 
RNA was extracted from frozen tiss�es by the Trizol 
reagent �Invitrogen�� USA���� according to the s�pplier’s 
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Aim: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages. Methods: We screened 
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protocol. Total RNA �3 μg�� samples were reverse 
transcribed to a final vol�me of �� μl�� �sing �� pM 
oligo-�dT��-primer �TaKaRa�� �apan���� � mM dNTP mix 
�TaKaRa�� �apan���� ��� U reverse transcriptase �Pro-
mega�� USA���� and � × b�ffer 4 μl. RT reactions were 
performed on Mastercycler �Eppendorf�� Germany��. 
RNA was treated for 3� min at 3�� °C by DNase before 
reverse transcription.
RT-PCR analysis survivin mRNA expression in 
ovarian tissues. We screened the positive expression 
of s�rvivin mRNA by RT-PCR in ��4 ovarian samples. 
The cDNA was amplified in a �� μl reaction vol�me 
containing � U Taq polymerase �Promega�� USA���� 
��� μM dNTP�� �.� mM MgCl��� � μl �� × polymerase 
chain reaction b�ffer�� and �� mM KCL. Specific pri-
mers for s�rvivin and β-actin were generated �sing 
the Primer 3 software and prepared by  Invitrogen 
Biotech. The seq�ences of the primers are shown in 
Table �. All PCRs were performed by Mastercycler 
�Eppendorf�� Germany��. The cycling conditions com-
prised a denat�ration step for � min at �� °C�� followed 
by 4� cycles of denat�ration ��� °C for 3� s���� anneal-
ing ��3 °C for 3� s�� and extension ���� °C for 3� s��. The 
PCR prod�cts were electrophoresed on a �% agarose 
gel�� stained with ethidi�m bromide ��.� μg/ml���� and 
vis�alized by an UV transill�minator �Alpha Innotech�� 
USA��.We �sed h�man β-actin as an internal marker. 
It was considered positive if PCR prod�ct was ��� bp 
by gel electrophoresis.
Table 1. Primers used for PCR
Survivin Antisense CTTTCTCAACGACCACCG 110 bp NM001168.2sense GTAGGTGACGGGGTGAC
β-Actin Antisense GTTGCGTTACACCCTTTC 152 bp NM001101.2sense CTGTCACCTTCACCGTTC
QRT-PCR analysis survivin mRNA expression 
levels in ovarian tisssues. QRT-PCR was �sed to 
determine relative s�rvivin mRNA expression levels in 
�� cases with s�rvivin �+�� ovarian tiss�es. QRT-PCR 
analysis was performed on Light Cycler �Roche Ap-
plied Science�� USA�� and on a vol�me of �� μl contain-
ing � μl of cDNA�� �� μl of �� × SYBR Green PCR Master 
Mix �TaKaRa�� �apan���� �.� μl of each primer ��� pM���� 
and 8 μl of DEPC-treated water. Primers for s�rvivin 
and β-actin were same as those �sed for RT-PCR. 
The program for detection s�rvivin was set at �� °C for 
�� s�� q�antification program ��� °C for � s�� �6 °C for 
� s�� and ��� °C for � s�� 83 °C for � s�� which was repeated 
�� times�� a melting c�rve program ��� °C for � s and 
6�°C for 3� s�� ��°C with a heating rate of �.� °C for � s 
and contin�o�s fl�orescence meas�rement���� and a 
cooling step to 4� °C for 3� s. The program for detected 
β-actin was set at �� °C for �� s�� q�antification ��� °C 
for � s�� �3 °C for � s�� and ��� °C for �� s�� which was 
repeated �� times�� a melting c�rve program ��� °C for 
� s and 6� °C for 3� s�� �� °C with a heating rate of �.� °C 
for � s and contin�o�s fl�orescence meas�rement���� 
and a cooling step to 4� °C for 3� s. A standard c�rve of 
cycle thresholds �sing serial dil�tions of cDNA samples 
were �sed to calc�late the relative ab�ndance. Melting 
c�rve analysis was performed to confirm prod�ction of 
a single prod�ct in each reaction. The specificity of the 
amplification prod�cts was verified f�rther by s�bject-
ing the amplification prod�cts to electrophoresis on a 
�% agarose gel. S�rvivin mRNA expression was nor-
malized to the expressed ho�sekeeping gene β-actin. 
The data was analyzed with Light Cycle software 4.� 
�Roche Applied Science�� USA��.
Statistical analysis. All statistical analyses were 
performed with the SPSS ��.� � software package 
for Windows �SPSS Inc�� Chicago�� IL��. The correlation 
between s�rvivin expression and clinicopathologic 
feat�res was statistically analyzed with the Chi-sq�are 
test and Fisher’s exact test. St�dent’s two-tailed t-test 
was �sed to compare data between two gro�ps. One-
way analysis of variance and Bonferroni’s correction 
were �sed to compare data between three or more 
gro�ps. P-val�e < �.�� was considered statistically 
significant.
results
RT-PCR analysis survivin mRNA expression in 
ovarian tissues. RT-PCR analysis showed that there 
were �� cases with positive s�rvivin mRNA expres-
sion from ��4 ovarian tiss�e samples�� incl�ding zero 
in normal ovarian tiss�es�� 46 ���3%�� in the 63 cases 
of ovarian carcinomas�� 8 �4��%�� in the �� cases of 
borderline ovarian carcinomas�� 4 ���%�� in �� cases of 
benign ovarian t�mors �Table ��� Fig. ��� Fig. ��� a��. The 
data on relationship between the vario�s clinicopatho-
logic feat�res and s�rvivin mRNA expression rate are 
described in Table �. A significant positive correlation 
�P = �.��6�� was observed between s�rvivin mRNA 
expression rate and histological grade �Fig. ��� b��. Of 
the 3� low-grade �G��G��� t�mors�� �8 �6�%�� showed 
s�rvivin mRNA expression. In contrast�� �� �84%�� of 
33 high-grade t�mors �G3�� were positive for s�rvivin 
mRNA expression. F�rthermore�� a significant cor-
relation �P = �.�4��� became evident between s�rvivin 
expression and clinical stage of the disease �Fig. ��� c��. 
��� �6�%�� cases with positive s�rvivin expression were 
related to stage I/II�� and �� �8�%�� cases to stage III/IV. 
The s�rvivin expression rate in ovarian carcinomas was 
associated with histological type �P = �.��8�� Fig. ��� d ���� 
b�t no correlation was fo�nd between s�rvivin expres-
sion and lymph node metastasis �P = �.����� Fig. ��� e�� 
or ascites �P = �.8���� Fig. ��� f�� .
Fig. 1. S�rvivin mRNA expression in ovarian tiss�es analyzed 
by RT-PCR. NOV: normal ovarian carcinoma�� BOVT: benign ova-
rian t�mor�� BOVC: borderline ovarian carcinoma�� OVC: ovarian 
carcinoma. Actin — ��� bp�� s�rvivin — ��� bp 
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Fig. 2. The rate of s�rvivin expression in ovarian tiss�e samples 
dependent on type of t�mor �a�� NOV: normal ovarian carcinoma�� 
BOVT: benign ovarian t�mor�� BOVC: borderline ovarian carcinoma�� 
OVC: ovarian carcinoma��; differentiation grade �b��; clinical stage �c��; 
histological type �d��; lymph node metastasis �e�� and ascites �f�� 
Table 2. Expression of survivin mRNA in ovarian tissue samples 
Sample Number of patients
Positive survivin 
expression (%) P-value
Normal ovarian tissue 11 0 (0%)
Benign ovarian tumor 21 4 (19%)
Borderline ovarian carcinoma 19 9 (47%)
Ovarian carcinoma 63 46 (73%)
Grade: 0.026
G1–G2 30 18 (60%)
G3 33 28 (84%)
FIGO stage:
0.049I–II 28 17 (60%)
III–IV 35 29 (82%)
Histological type:  
0.008serous 42 35 (76%)
mucinous 12 8 (66%)
endometrioid 9 3 (33.3%)
Lymph node metastasis: 0.921
Yes 34 25 (73%)
No 29 21 (72%)
Ascites: 0.87
yes 36 26 (72%)
No 27 20 (74%)
QRT-PCR analysis survivin mRNA expression 
levels. QRT-PCR was �sed to determine relative expres-
sion levels of the s�rvivin gene in �� cases with s�rvivin 
�+�� ovarian tiss�es. The res�lts demonstrated that higher 
levels of s�rvivin/β-actin mRNA expression in ovarian car-
cinoma ��.���� ± �.��486�� than that in borderline ovarian 
carcinoma tiss�es ��.���� ± �.���88�� and benign ovarian 
t�mor tiss�es ��.����� ± �.�������. There was statistical 
difference among them �P < �.���� Fig. 3�� a��. The res�lts 
also demonstrated that there was significant difference of 
mean s�rvivin/ β-actin mRNA expression levels between 
G��G� and G3 in ovarian carcinoma ��.���4 ± �.��348 
vers�s �.��4� ± �.���33�� P = �.�4��� Fig. 3�� b��. In advanced 
stage �III/IV�� cancers�� the mean s�rvivin/β-actin mRNA 
expression levels were higher than that in early-stage �I/II�� 
cancers ��.���4 ± �.��3�6 vers�s �.��4� ± �.���3���� P = 
�.�4��� Fig. 3�� c��. F�rthermore�� we fo�nd that the mean 
s�rvivin mRNA levels were higher in cases with lymph 
node metastasis than that witho�t lymph node metastasis 
��.���3 ± �.��3�� vers�s �.��44 ± �.���46�� P = �.�3��� 
Fig. 3�� d��. No statistical difference �P > �.���� Fig. 3�� e�� 
was identified in s�rvivin expression among sero�s can-
cers�� endometrioid and m�cino�s�� no statistic difference 
�P > �.���� Fig. 3�� f�� to ascites either �Table 3��.
Fig. 3. S�rvivin/actin mRNA expression levels in ovarian tiss�es 
meas�red by real time PCR depenedent on on type of t�mor �a�� 
NOV: normal ovarian carcinoma�� BOVT: benign ovarian t�mor�� 
BOVC: borderline ovarian carcinoma�� OVC: ovarian carcinoma��; 
differentiation grade �b��; clinical stage �c��; histological type �d��; 
lymph node metastasis �e�� and ascites �f��
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Table 3. Survivin/β-actin mRNA expression levels
Sample Survivin/β-actin mRNA ex-pression levels (means ± SD) P-value
Benign ovarian tumor 0.0007 ± 0.00011
Borderline ovarian carcinoma 0.0055 ± 0.00188 < 0.001
Ovarian carcinoma 0.0122 ± 0.00486
Grade:
G1–G2 0.0104 ± 0.00348 0.041
G3 0.0142 ± 0.00533
FIGO stage:
I–II 0.0104 ± 0.00316 0.041
III–IV 0.0141 ± 0.00537
Histological type: 
serous 0.0133 ± 0.00525 0.673 (s vs m)
mucinous 0.0123 ± 0.00478 0.600 (s vs e)
endometrioid 0.0177 ± 0.00562 0.856 (m vs e)
Lymphonode metastasis:
Yes 0.0103 ± 0.00302 0.031
No 0.0144 ± 0.00546
Ascites:
yes 0.0137 ± 0.00518
no 0.0125 ± 0.00526 0.563
discussion
Ovarian carcinoma is among the most common 
female cancers and the leading ca�se of death from 
gynecologic malignancy in the world. Altho�gh the 
clinical and histological prognostic factors �e. g. t�mor 
grade and clinical stage�� had been reported to be of 
prognostic significance in ovarian cancer [��]�� it is 
conceivable that the assessment of biochemical factors 
more strictly related to t�mor cell biology and intrinsic 
aggressiveness co�ld help identifying high-risk patients 
and facilitating management of this disease.
Cell proliferation and cell death pathways meet at a 
pivotal crossroad�� cr�cial to maintain normal homeo-
stasis and to eliminate dangero�s cells before they 
start dividing. S�rvivin is an intrig�ing and fascinating 
protein at this crossroad that interfaces life and death�� 
thro�gh its d�al role in facilitating cell division and 
enco�ntering apoptosis [��]. S�rvivin promotes cell 
proliferation and enhances angiogenesis�� it may play 
an important role in protecting abnormal cells from 
apoptosis d�ring cell division�� which contrib�tes to 
t�mor development and prognosis [����3]. 
Several st�dies had shown that s�rvivin mRNA ex-
pression levels correlated with the prognosis in s�ch 
carcinomas as osteosarcoma and myelodysplastic 
syndrome [�3��4]. Only the expression rate of s�rvivin 
has been reported to be associated with progress and 
prognosis of ovarian carcinoma in some literat�res 
[����8]�� b�t little is known abo�t the relationship bet-
ween the expression levels of s�rvivin and prognosis 
of ovarian carcinoma. 
In o�r experiment we testified that the rate of 
s�rvivin expression is associated with progression of 
ovarian carcinoma and some other parameters �FIGO 
stage�� differentiation grade�� and histological type��. 
Moreover�� we fo�nd that s�rvivin expression levels 
were different in s�rvivin positive tiss�es. S�rvivin ex-
pression levels were the highest in ovarian carcinomas�� 
and there were the lowest s�rvivin expression levels in 
benign ovarian t�mor tiss�es. F�rthermore�� s�rvivin 
expression levels are associated with the FIGO stage�� 
grade�� and lymph node metastasis�� b�t not with ascites 
and histological type in ovarian carcinoma.
In this st�dy we determined not only whether s�r-
vivin gene was expressed or not�� b�t also the levels of 
s�rvivin expression in ovarian carcinoma. One can �se 
real time PCR to detect the mRNA expression of ova-
rian tiss�es by biopsy. F�rthermore�� s�rvivin is �nder 
st�dy as a novel target for the treatment of cancer�� 
and its expression may be reg�lated by different ap-
proaches [�4��6].
The relationships between s�rvivin expression 
levels and the s�rvival rate or the reaction to chemo-
therapy of patients with ovarian carcinoma were not 
showed in the present st�dy�� beca�se of the lack of the 
follow-�p. F�rther long-term follow-�p st�dies wo�ld 
be done in f�t�re to address these q�estions.
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Экспрессия сурвивина в ткани при раке яичника 
Цель: исследовать экспрессию сурвивина в доброкачественных и злокачественных новообразованиях яичника. Методы: экспрес-
сия мРНК сурвивина исследована методом RT-PCR в 114 образ�ах ткани яичника человека.�ля установления уровня экспресии           
мРНК сурвивина применяли количественный PCR в режиме реального времени. Результаты: экспрессия мРНК сурвивина 
не выявлена в образ�ах нормальной ткани яичника, но зарегистрирована в 73% случаев рака яичника, 47% случаев  серозных 
опухолей яичника серозного типа и 19% образ�ов доброкачественных опухолей. Установлена положительная зависимость между 
уровнем экспрессии мРНК сурвивина и клинической стадией заболевания (P = 0,026), и степенью дифферен�ировки опухоли 
(P = 0,049). Выявлена статистически значимая зависимость уровня экспрессии мРНК сурвивина от гистологического типа 
опухоли (серозного, мукозного, эндометриоидного, P = 0,008) и отсутствие таковой от наличия метастазов в лимфатических 
узлах (P = 0.921) или ас�ита (P = 0.87). Также установлено, что средние уровни экспрессии мРНК сурвивина выше при раке 
яичника, чем в ткани доброкачественных новобразований или серозных опухолей яичника пограничного типа (P < 0,001). 
При раке яичника высокий уровень экспрессии мРНК сурвивина коррелировал с клинической стадией заболевания, степенью 
дифферен�ировки опухолевых клеток, но не коррелировал с гистологическим типом новообразования. Выводы: результаты 
свидетельствуют о том, что экспрессия сурвивина ассо�иирована с прогрессией рака яичника.
Ключевые слова: сурвивин, рак яичника, опухолевая прогрессия.
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